NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Lincoln Pharma Q3 FY26 Net Profit Rises 37.7% to INR 28.6 Cr; Eyes INR 1,000 Cr Revenue Target
Lincoln Pharmaceuticals reported a strong Q3 FY26 with revenue growing 13.5% YoY to INR 166.32 crores and net profit jumping 37.7% to INR 28.60 crores. The management maintains a long-term revenue target of INR 1,000 crores, driven by the expansion of the Cepha block and entry into regulated markets. A new R&D center is expected to be operational within 2.5 months to support niche therapeutic product development. The company remains debt-free with significant cash reserves being deployed for potential inorganic growth opportunities.
முக்கிய அம்சங்கள்
Net Profit increased by 37.7% YoY to INR 28.60 crores in Q3 FY26 compared to INR 20.77 crores in Q3 FY25.Revenue from operations grew to INR 166.32 crores from INR 146.55 crores in the previous year.Cepha block revenue is targeted to reach INR 90-100 crores next year, up from the current INR 45 crores.EPS for the 9-month period reached INR 38.07, nearly matching the previous full year's EPS of INR 41.11.Company is debt-free and exploring inorganic growth opportunities using substantial cash reserves yielding 10-12% returns.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the new R&D center and the ramp-up of the Cepha block as key drivers for the INR 1,000 crore revenue goal. The company's debt-free status and strong cash position provide a safety margin for long-term growth.
Linc Limited Q3 FY26: Revenue Up 5.8% to ₹129.3 Cr, PAT Margins Contract to 5.2%
Linc Limited reported a modest 5.8% YoY revenue growth to ₹129.29 crores for Q3 FY26, though PAT margins contracted by 191 bps to 5.2%. Operating EBITDA margins stood at 10%, impacted by a one-time labor regulation expense; excluding this, adjusted margins were 10.7%. While volumes grew to 16.4 crore units, the average selling price (ASP) declined to ₹5.0 from ₹6.3 due to a strategic shift toward the mass-market ₹5 segment. The company faces a delay in its Bengal manufacturing facility, now expected in Q1 FY27, but maintains a healthy net free cash position of ₹10.14 crores.
முக்கிய அம்சங்கள்
Operating income grew 5.8% YoY to ₹129.29 crores, while PAT stood at ₹6.77 crores.Writing instrument volumes rose to 16.4 crore units, with the Pentonic brand contributing 6.5 crore units.Adjusted EBITDA margin was 10.7% after excluding a one-time non-recurring employee benefit expense.Average Selling Price (ASP) declined to ₹5.0 due to a deliberate product mix shift toward the ₹5 MRP segment.The Bengal manufacturing facility is delayed and is now expected to become operational by Q1 FY27.
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the lower-priced product mix on long-term profitability and track the timely commissioning of the Bengal facility in FY27. The strong cash flow from operations of ₹33.81 crores provides a buffer during this investment phase.
Linc Ltd Q3 FY26 PAT Drops 22.3% YoY to ₹6.77 Cr Amid Margin Pressures
Linc Limited reported a modest 5.8% YoY growth in operating income to ₹129.29 crore for Q3 FY26, but profitability faced significant headwinds. Operating EBITDA declined by 11.7% YoY to ₹12.90 crore, with margins contracting to 10.0% due to higher employee costs and regulatory changes. Net profit fell 22.3% YoY to ₹6.77 crore, further impacted by ₹0.83 crore in losses from strategic joint ventures. Despite these pressures, the company remains debt-free with a net cash position of ₹10.14 crore and is expanding its product portfolio into high-margin stationery.
முக்கிய அம்சங்கள்
Operating Income grew 5.8% YoY to ₹12,929 Lacs, though it declined 7% on a sequential basis.Operating EBITDA margin contracted by 198 bps YoY to 10.0%, impacted by one-time employee benefit expenses.Profit After Tax (PAT) declined by 22.3% YoY to ₹677 Lacs, further weighed down by ₹83 Lacs in JV losses.Maintains a strong balance sheet with a negative Net Debt of ₹1,014 Lacs and an annualized ROCE of 17.3%.The upcoming Bengal manufacturing facility is slightly behind schedule, now expected to be operational by Q1 FY27.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of operating margins and the successful commissioning of the Bengal facility in FY27. While short-term profitability is under pressure, the company's debt-free status and focus on premiumization remain long-term positives.
Lincoln Pharma Q3 Net Profit Surges 37.7% YoY to ₹28.6 Crore; Revenue Up 13.5%
Lincoln Pharmaceuticals reported a strong performance for the quarter ended December 31, 2025, with consolidated net profit rising 37.7% YoY to ₹28.60 crore. Revenue from operations grew by 13.5% YoY to ₹166.32 crore, supported by steady growth in its core pharmaceutical business. The company's profitability improved significantly on a sequential basis, with net profit jumping 43.1% compared to the previous quarter. For the nine-month period, the company maintained a healthy trajectory with a net profit of ₹76.26 crore on revenues of ₹483.75 crore.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations grew 13.5% YoY to ₹166.32 crore in Q3 FY26Net Profit for the quarter stood at ₹28.60 crore, up from ₹20.77 crore in the same period last yearEarnings Per Share (EPS) increased to ₹14.28 from ₹10.37 in Q3 FY25Profit Before Tax (PBT) rose to ₹34.72 crore, reflecting improved operational efficiencyNine-month (9M FY26) revenue reached ₹483.75 crore with a net profit of ₹76.26 crore
👀 கவனிக்க வேண்டியவை
The strong YoY and QoQ growth in profitability suggests robust operational performance. Investors should monitor the sustainability of these margins and the company's expansion in the pharmaceutical segment.
Linc Ltd Q3 FY26 PAT Declines 15.7% YoY to ₹7.46 Cr; Revenue Up 6.3% YoY
Linc Limited reported a mixed performance for the quarter ended December 31, 2025, with revenue from operations growing 6.3% YoY to ₹125.48 crore. However, profitability faced significant pressure as Net Profit (PAT) declined by 15.7% YoY to ₹7.46 crore, down from ₹8.85 crore in the previous year's quarter. The company also saw a sequential decline in revenue and profit compared to Q2 FY26. A one-time impact of ₹87.78 lakhs was recorded due to new Labour Code valuations, and the company is currently contesting a GST demand of ₹353.39 lakhs.
முக்கிய அம்சங்கள்
Revenue from operations stood at ₹12,548.21 lakhs, up 6.3% YoY but down 7.5% QoQ.Profit After Tax (PAT) fell to ₹745.88 lakhs compared to ₹884.90 lakhs in Q3 FY25.Earnings Per Share (EPS) decreased to ₹1.25 from ₹1.49 in the corresponding quarter last year.Employee benefit expenses included a ₹87.78 lakh incremental impact from the new Labour Code actuarial valuation.The company is contesting a GST demand and penalty totaling over ₹706 lakhs related to HSN classification.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin contraction as profits have declined despite revenue growth. The pending GST litigation and the impact of rising stock-in-trade costs are key risks to watch in the near term.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CRISIL Reaffirms Lincoln Pharmaceuticals' Credit Rating at 'CRISIL A/Stable' and 'CRISIL A1'
CRISIL has reaffirmed Lincoln Pharmaceuticals' long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for its Rs 102 crore bank facilities. The company maintains a robust financial profile with zero debt and a healthy net worth of Rs 671 crore as of March 31, 2025. Revenue grew by 14% YoY to Rs 623 crore in FY25, supported by a strong export presence contributing 60-65% of total sales. While the liquidity position is strong with Rs 173.1 crore in liquid investments, investors should monitor the increase in loans to affiliates, which rose to Rs 141 crore.
முக்கிய அம்சங்கள்
CRISIL reaffirmed long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for Rs 102 crore facilities.Company reported zero debt as of March 31, 2025, with a high interest coverage ratio of 91.01 times.Revenue grew 14% year-on-year to Rs 623.23 crore in FY25, driven by 1,700 registered products.Liquid investments in shares, debentures, and mutual funds stood at Rs 173.1 crore.Loans and advances to affiliates increased to Rs 141 crore from Rs 104 crore in the previous year.
👀 கவனிக்க வேண்டியவை
The reaffirmation of ratings and zero-debt status highlights the company's strong solvency and financial health. Investors should remain positive but monitor the rising loans to affiliates and the working capital cycle.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
